At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 52 enrolled
Drug / intervention
LY3475070 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1 Multicenter Global First in Human Study of the CD73 Inhibitor LY3475070 as Monotherapy or in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
In Brief
A Phase 1 clinical trial evaluating LY3475070 and Pembrolizumab for Advanced Cancer. Completed, enrolled 52 participants across 12 sites in 3 countries.
Detailed Summary
The reason for this study is to see if the CD73 inhibitor LY3475070 alone or in combination with pembrolizumab is safe and effective in participants with advanced cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Cancer
CountriesAustralia, United Kingdom, United States
CollaboratorsMerck Sharp & Dohme LLC
Timeline
Phase 1CompletedFinished
2020202120222023202420252026
First PostedNov 2019
Enrollment StartJan 2020
Primary CompletionMay 2021
Study CompletionJun 2022
TodayJul 2026
First PostedNov 4, 2019
Enrollment StartJan 16, 2020
Primary CompletionMay 12, 2021
Study CompletionJun 20, 2022
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 6.7 years ago
Interventions
LY3475070drug
Administered orally
Pembrolizumabdrug
Administered IV